SkipNav
Press Release Detail
YNHH
    

YNHH: a certified destination therapy center for permanent ventricular assist devices

2/22/2011 — Yale-New Haven Hospital (YNHH) has received certification from the Joint Commission - the nation's predominant standards-setting and accrediting body in health care - to implant left ventricular assist devices (LVADs) into patients with end-stage heart failure as a permanent or destination therapy, not just as a temporary bridge to transplant. The LVAD, which performs the pumping for the heart, is implanted into the abdomen, allowing patients to pursue their regular daily activities.

Destination therapy is an alternative to transplantation for patients with end-stage heart failure who do not qualify or are ineligible for heart transplant. By implanting a long-term LVAD, patients who are not candidates for a heart transplant have the opportunity to live more independently with a longer and higher-quality life.

"This certification allows us to have a tremendous impact on the lives of patients with advanced heart failure, who have no other viable options," said Donald Botta, MD, surgical director of cardiac transplantation and mechanical circulatory support at YNHH. "Without LVAD therapy, the two-year survival rate for these patients is less than ten percent, a prognosis worse than almost every cancer. With support from the new generation of LVADs, survival has improved seven-fold, and continues to improve."

As part of the Joint Commission certification process, YNHH underwent an extensive, onsite evaluation by a Joint Commission reviewer. To be certified, a hospital must meet several criteria, including having a surgeon with experience in implantable devices as well as a specialized team dedicated to doing the procedure.

YNHH Heart and Vascular Center is a national pioneer in developing new heart treatments and therapies. As Connecticut's premier referral center, the Center receives some of the most difficult heart patients from throughout New England - patients who come for heart transplants, high-risk valve or bypass surgery and angioplasty, as well as those who have irregular heart rhythms requiring an expert cardiologist. In 1984, Yale-New Haven cardiac surgeons performed Connecticut's first heart transplant, and in 1987, began implanting Novacor artificial heart devices.

 
Yale-New Haven Hospital news release
ynhhpublicrelations@ynhh.com

Yale-New Haven Hospital is a nationally recognized, 1,541-bed, not-for-profit hospital serving as the primary teaching hospital for the Yale School of Medicine. Yale-New Haven was founded as the fourth voluntary hospital in the U.S. in 1826. Today, the hospital's two New Haven-based inpatient campuses include Yale-New Haven Children's Hospital, Yale-New Haven Psychiatric Hospital and Smilow Cancer Hospital. YNHH has a combined medical staff of about 4,500 university and community physicians practicing in more than 100 specialties. YNHH's York Street campus and associated ambulatory sites are Magnet-designated by the American Nurses Credentialing Center.

Contact Us

ynhhpublicrelations@ynhh.org



Yale School of Medicine
Magnet Recognition Best Hospitals 2012-2013

Video Library

Video Library